Speakers:
– Alisa Serio, Executive Director of Microbiology and Nonclinical Development, Paratek Pharmaceuticals (USA)
– Victoria Savage, Chief Scientific Officer, INFEX Therapeutics Ltd (UK)
Moderator:
– Daniel Ritz, Senior Director – Senior Group Leader Biology Technologies / Lead Discovery, Idorsia Pharmaceuticals Ltd. (Switzerland)
This webinar will feature two presentations from those developing non-traditional antibacterials as potential solutions to combat infections.
Presentation 1: Progression criteria and go/no go decisions in antibacterial drug discovery – a perspective from Paratek Pharma (Alisa Serio)
– Overview of the drug discovery process through approval & commercialization
– Strategic considerations for each phase of an antibacterial program
– How non-dilutive funding can play a key role in SME programs
– Examples of go/no-go decisions
Presentation 2: Progressing an antibacterial drug discovery program – a perspective from INFEX Therapeutics (Victoria Savage)
– Introduction to the role of SMEs in antibacterial drug development
– Where SMEs fit in the development pipeline
– Challenges for SMEs
– Case studies for successful and unsuccessful programs
This live webinar includes an interactive Q&A session.
Date and time:
27 June 2024 at 17:00-18:30 CEST.
Dedicated registration link here
